Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GDUFA II: FDA, Industry Reach Tentative 'Alignment' On ANDA Review Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

Negotiations to renew user fee program continue as finance issues remain unresolved.


Related Content

Generic User Fee Talks Reach 'Final Wording' But Still Not Done
GDUFA Negotiations Shift To 'Tiered' Fee Models
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods